Priya Uday Kumthekar MD

Neurology•Chicago, IL

Instructor in Ken and Ruth Davee Department of Neurology

Join to View Full Profile

675 N Saint Clair StSte 20-100Chicago, IL 60611
Phone+1 312-695-4360
Fax+1 312-695-1435

Education & Training

McGaw Medical Center of Northwestern UniversityResidency, Neurology, 2008 - 2011
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 2007 - 2008
Northeast Ohio Medical UniversityClass of 2007

Certifications & Licensure

FL State Medical License 2024 - Present
IL State Medical License 2011 - 2026
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE_NOT_RECRUITING
PHASE3
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Start of enrollment: 2010 Jun 17
Completed
Phase 2
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy Start of enrollment: 2013 Nov 27
Completed
Phase 2
ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Start of enrollment: 2014 Apr 01
Completed
Phase 2
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
COMPLETED
PHASE1, PHASE2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma Start of enrollment: 2016 Aug 01
RECRUITING
PHASE2
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery Start of enrollment: 2017 May 25
Completed
Early Phase 1
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2020 Jun 08
TERMINATED
PHASE1, PHASE2
Roles: Principal Investigator, Contact
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10
RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator, Contact
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers Start of enrollment: 2017 Jul 13
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Longitudinal CSF Tumor Cell Enumeration and Mutational Analysis as a Driver for Leptomeningeal Disease Management.
Arushi Tripathy, Pericles Corkos, Barbara Blouw, Deondra A Montgomery, Melissa Moore
Cancers. 2025-02-27
1 citations
NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.
Emilie Le Rhun, Lakshmi Nayak, Mary Jane Lim-Fat, Roberta Rudà, Elena Pentsova
Neuro-Oncology. 2025-02-10
1 citations
Clinical outcomes for pleomorphic xanthoastrocytoma patients.
Jared J Sullivan, James P Chandler, Maciej S Lesniak, Matthew C Tate, Adam M Sonabend
Neuro-Oncology Practice. 2025-02-01

Lectures

A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.
2019 ASCO Annual Meeting - 6/1/2019
A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Combination Therapy Does Not Extend Survival in GlioblastomaNovember 20th, 2024
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of GlioblastomaSeptember 9th, 2024
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss Its Proprietary CNSide™ Assay to Detect and Quantify Cancer That Metastasized to the Central Nervous SystemOctober 6th, 2022
Join now to see all